HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo's Turnaround Tools: 'National Brand,' Novel NRTs, CBD And Natural Products, Sponsoring OTC Switches

Executive Summary

Following investor day conference, market analysts gave Perrigo points for an ambitious three-year plan while also noting the degree of difficulty it faces in succeeding. Other changes planned to stem slump sales and earnings slump include potentially getting into CBD supplement space and getting back into VMS manufacturing after leaving the sector in one of several moves since 2015 intended to help drive net income and improve its margin.

You may also be interested in...



Private Label OTC Giant Stretches For Switch Help

HRA brings needed expertise in OTC switches to Perrigo, which regularly is first to launch generic equivalents for brand switches but its name hasn’t been linked to submitting proposals for making additional drug ingredients available OTC.

Perrigo Offloads LATAM Business In Push To Cut Costs And Improve Margins

Perrigo has struck a deal with Advent International to offload its "sub scale" and margin-dilutive OTC businesses in Mexico and Brazil.

Perrigo Adds University Research To Tool Box With Deals And Pipeline For Self-Care Market Growth

“Formal partnership” connects Michigan State's clinical and research expertise with Perrigo's product innovation, manufacturing scale and retail distribution network, Despite breadth and depth of Perrigo’s product lineup, it expects another $1b annually could come from segments where it has no or little market share.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel